颈动脉内膜剥脱术与颈动脉支架置入术后并发症相关住院费用的比较
基于Premier医疗数据库2009至2015年100185例颈动脉内膜剥脱术(CEA,n=86035)或颈动脉支架置入术(CAS,n=14150)患者的回顾性分析显示,CAS较CEA的卒中调整比值比高1.55倍、死亡调整比值比高2.60倍,心肌梗死风险无显著差异;CEA的卒中调整增量费用显著高于CAS约2000美元,无症状患者中为5284美元 vs 2932美元(p<0.01)。作者认为CEA因并发症率和基线费用较低仍是更具成本效益的颈动脉干预方式,但需长期成本效益研究方可定论。
要点
- CAS较CEA的卒中调整比值比高1.55倍、死亡调整比值比高2.60倍,心肌梗死风险无显著差异。
- CEA的卒中调整增量费用显著高于CAS约2000美元,无症状患者中为5284美元 vs 2932美元(p<0.01)。
- 作者认为CEA因并发症率和基线费用较低仍是更具成本效益的颈动脉干预方式。
核心结论
- CEA的院内卒中增量费用相对高于CAS,但作者认为CEA因并发症率和基线费用较低仍是更具成本效益的颈动脉干预方式,需长期成本效益研究方可定论。
研究设计与样本
- 回顾性分析Premier医疗数据库2009至2015年100185例患者(平均年龄70.7±9.5岁,58.3%男性),其中CEA 86035例、CAS 14150例。
- 采用多变量logistic模型分析二分类结局、广义线性模型分析住院费用,结局以调整比值比(aOR)及95%置信区间(CI)呈现。
主要发现
- CAS较CEA的卒中调整比值比高1.55倍[aOR 1.55(95%CI 1.36至1.77),p<0.001]。
- CAS较CEA的死亡调整比值比高2.60倍[aOR 2.60(95%CI 2.14至3.17),p<0.001]。
- 两种手术的心肌梗死风险无显著差异。
- 死亡和心肌梗死的调整增量费用在两种手术间相似。
- CEA的卒中调整增量费用显著高于CAS约2000美元;按症状状态分层,该差异主要见于无症状患者(5284美元 vs 2932美元,p<0.01)。
临床怎么用
- 作者认为CEA因并发症率和基线费用较低仍是更具成本效益的颈动脉干预方式。
- 作者提出需长期成本效益研究方可作出明确结论。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To quantify and compare the incremental cost associated with in-hospital stroke, death, and myocardial infarction (MI) after carotid endarterectomy (CEA) vs carotid artery stenting (CAS). METHODS: A retrospective analysis was performed of 100,185 patients (mean age 70.7±9.5 years; 58.3% men) who underwent CEA (n=86,035) or CAS (n=14,150) between 2009 and 2015 and were entered into the Premier Healthcare Database. Multivariate logistic models and generalized linear models were used to analyze binary outcomes and hospitalization costs, respectively. Outcomes are presented as the adjusted odds ratio (aOR) and 95% confidence interval (CI). RESULTS: CAS was associated with 1.6 times higher adjusted odds of stroke [aOR 1.55 (95% CI 1.36 to 1.77), p<0.001] and with 2.6 times higher odds of death [aOR 2.60 (95% CI 2.14 to 3.17), p<0.001] compared with CEA. There was no significant difference in MI risk between the 2 procedures. The adjusted incremental cost of death and MI were similar between the 2 procedures. However, the adjusted incremental cost of stroke was significantly higher in CEA compared with CAS by an estimated $2000. When stratified with respect to symptomatic status, the increased adjusted incremental cost of stroke in CEA was mainly seen in asymptomatic patients ($5284 vs $2932, p<0.01). CONCLUSION: The incremental cost of in-hospital stroke is relatively higher in CEA compared to CAS. However, CEA remains a more cost-effective carotid intervention due to lower complication rates and baseline costs compared with CAS. Long-term cost-effectiveness studies are needed before definite conclusions are made.
引用
- Dakour-Aridi H, Nejim B, Locham S, et al. Complication-Specific In-Hospital Costs After Carotid Endarterectomy vs Carotid Artery Stenting. J Endovasc Ther. 2018. PMID: 29893167. doi:10.1177/1526602818781580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。